ESSA Pharma (EPIX) Reaches New 12-Month Low at $0.21

ESSA Pharma Inc. (NASDAQ:EPIX) (TSE:EPI) shares reached a new 52-week low on Monday . The stock traded as low as $0.21 and last traded at $0.24, with a volume of 11300 shares trading hands. The stock had previously closed at $0.25.

EPIX has been the topic of several recent analyst reports. Zacks Investment Research raised ESSA Pharma from a “hold” rating to a “buy” rating and set a $0.50 price target on the stock in a research report on Monday, September 11th. Bloom Burton lowered ESSA Pharma from a “buy” rating to a “hold” rating in a research report on Tuesday, September 12th. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $4.75.

The company has a debt-to-equity ratio of -3.00, a current ratio of 2.32 and a quick ratio of 2.32.

ILLEGAL ACTIVITY NOTICE: This report was posted by Stock Observer and is the sole property of of Stock Observer. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at https://www.thestockobserver.com/2017/12/11/essa-pharma-epix-reaches-new-12-month-low-at-0-21.html.

About ESSA Pharma

ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses on the development of novel and proprietary therapies for the treatment of prostate cancer. Its product candidate is EPI-506, an oral small molecule pro-drug that is in Phase 1/2 clinical trial, which blocks the N-terminal domain of the androgen receptor.

Receive News & Ratings for ESSA Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply